Humacyte (HUMA) News Today $2.37 -0.04 (-1.66%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.38 +0.00 (+0.21%) As of 06/13/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HUMA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Humacyte, Inc. (NASDAQ:HUMA) Receives $11.71 Consensus Price Target from BrokeragesJune 15 at 2:09 AM | americanbankingnews.comHumacyte (NASDAQ:HUMA) Stock Rating Lowered by Wall Street ZenJune 14 at 2:11 AM | americanbankingnews.comHumacyte (NASDAQ:HUMA) Downgraded by Wall Street Zen to SellWall Street Zen downgraded Humacyte from a "hold" rating to a "sell" rating in a research report on Saturday.June 14 at 2:10 AM | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of "Buy" by AnalystsShares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, six have issuedJune 12 at 3:56 AM | marketbeat.comHumacyte: Revenue Ramp From Symvess IncomingJune 11, 2025 | seekingalpha.comCantor Fitzgerald Estimates Humacyte FY2026 EarningsJune 11, 2025 | americanbankingnews.comHumacyte (NASDAQ:HUMA) Receives "Buy" Rating from D. Boral CapitalJune 11, 2025 | americanbankingnews.comCantor Fitzgerald Predicts Humacyte FY2026 EarningsHumacyte, Inc. (NASDAQ:HUMA - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Humacyte in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($0.49) for the year.June 10, 2025 | marketbeat.comD. Boral Capital Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of Humacyte in a report on Monday.June 9, 2025 | marketbeat.comResults from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery MeetingJune 9, 2025 | theglobeandmail.comResults from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery MeetingJune 9, 2025 | globenewswire.comHumacyte Paradoxically Scales Back As Symvess Begins Its Long JourneyJune 9, 2025 | seekingalpha.comHumacyte, Inc. (NASDAQ:HUMA) Short Interest Up 20.7% in MayHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 30,350,000 shares, an increase of 20.7% from the April 30th total of 25,150,000 shares. Approximately 24.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 4,450,000 shares, the short-interest ratio is currently 6.8 days.June 4, 2025 | marketbeat.comNuveen Asset Management LLC Lowers Stake in Humacyte, Inc. (NASDAQ:HUMA)Nuveen Asset Management LLC cut its holdings in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 25.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 294,392 shares of the company's stock after selling 100,748 shares during the quartJune 4, 2025 | marketbeat.comTommy Tuberville traded these 4 stocks at the perfect time: Why they raised red flagsJune 4, 2025 | msn.comHumacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3June 2, 2025 | globenewswire.comHumacyte, Inc. (NASDAQ:HUMA) Shares Bought by Bank of America Corp DEBank of America Corp DE boosted its position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 160.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 597,319 shares of the company's stock after buyJune 1, 2025 | marketbeat.comIs Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?May 30, 2025 | finance.yahoo.comMillennium Management LLC Sells 348,653 Shares of Humacyte, Inc. (NASDAQ:HUMA)Millennium Management LLC lessened its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 27.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 918,854 shares of the company's stock after sellinMay 30, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Shares Sold by Voloridge Investment Management LLCVoloridge Investment Management LLC trimmed its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 60.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 499,202 sMay 29, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Holdings Decreased by Two Sigma Investments LPTwo Sigma Investments LP reduced its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 14.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 919,097 shares of the companMay 29, 2025 | marketbeat.comWaverly Advisors LLC Buys 211,009 Shares of Humacyte, Inc. (NASDAQ:HUMA)Waverly Advisors LLC lifted its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 331.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 274,579 shares of the company's stock after purchasing an additionalMay 25, 2025 | marketbeat.comWoodline Partners LP Has $14.39 Million Holdings in Humacyte, Inc. (NASDAQ:HUMA)Woodline Partners LP lifted its holdings in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 235.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,848,802 shares of the company's stock after purchasing an additioMay 24, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Buy" by AnalystsShares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have earned a consensus recommendation of "Buy" from the eight research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, six have assigned a buy recommenMay 20, 2025 | marketbeat.comQ3 Earnings Estimate for Humacyte Issued By HC WainwrightHumacyte, Inc. (NASDAQ:HUMA - Free Report) - Stock analysts at HC Wainwright issued their Q3 2025 earnings estimates for Humacyte in a research note issued to investors on Wednesday, May 14th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($0.13) per share foMay 20, 2025 | marketbeat.comHumacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NasdaqMay 19, 2025 | globenewswire.comHumacyte (NASDAQ:HUMA) Earns "Buy" Rating from D. Boral CapitalD. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research report on Tuesday.May 15, 2025 | marketbeat.comEarnings call transcript: Humacyte Q1 2025 beats EPS forecast, stock surgesMay 14, 2025 | investing.comDurham firm with battered stock cuts jobs to save cashMay 14, 2025 | bizjournals.comHumacyte, Inc. (NASDAQ:HUMA) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comQ1 2025 Humacyte Inc Earnings CallMay 14, 2025 | finance.yahoo.comHumacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026May 14, 2025 | msn.comHumacyte, Inc. (HUMA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comHumacyte Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comHumacyte Q1 2025 Earnings PreviewMay 12, 2025 | msn.comExploring Humacyte's Earnings ExpectationsMay 12, 2025 | benzinga.comHumacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025May 9, 2025 | globenewswire.comBrevan Howard Capital Management LP Boosts Stake in Humacyte, Inc. (NASDAQ:HUMA)Brevan Howard Capital Management LP lifted its holdings in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 2,795.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 876,340 shares of the companyMay 8, 2025 | marketbeat.comFirst Trust Advisors LP Takes Position in Humacyte, Inc. (NASDAQ:HUMA)First Trust Advisors LP bought a new position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 340,552 shares of the company's stMay 8, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Holdings Lowered by Marshall Wace LLPMarshall Wace LLP decreased its stake in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 90.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 54,917 shares of the company's stock after selling 529,645 shares during the quarter.May 7, 2025 | marketbeat.comHumacyte (HUMA) to Release Earnings on FridayHumacyte (NASDAQ:HUMA) will be releasing its Q1 2025 earnings before the market opens on Friday, May 9. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-9-humacyte-inc--stock/)May 4, 2025 | marketbeat.comHumacyte Insiders Placed Bullish Bets Worth US$949.4kApril 30, 2025 | finance.yahoo.comCantor Fitzgerald Increases Earnings Estimates for HumacyteHumacyte, Inc. (NASDAQ:HUMA - Free Report) - Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for shares of Humacyte in a report issued on Wednesday, April 23rd. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($0.71) per share forApril 27, 2025 | marketbeat.comJump Financial LLC Has $474,000 Holdings in Humacyte, Inc. (NASDAQ:HUMA)Jump Financial LLC trimmed its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 71.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 93,763 shares of the company's stock after selling 233,859 shares during the qApril 27, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Buy" by AnalystsShares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, six have given a buy rating anApril 25, 2025 | marketbeat.com$5K Birth Reward in Talks; Zepbound Lawsuits; Varenicline for Vape CessationApril 24, 2025 | msn.comHumacyte Challenges FDA Petition Amidst ControversyApril 18, 2025 | tipranks.comShamik J. Parikh Buys 7,500 Shares of Humacyte, Inc. (NASDAQ:HUMA) StockHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) insider Shamik J. Parikh purchased 7,500 shares of Humacyte stock in a transaction on Thursday, April 10th. The shares were purchased at an average cost of $1.55 per share, with a total value of $11,625.00. Following the transaction, the insider now owns 7,500 shares in the company, valued at approximately $11,625. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.April 16, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) CFO Dale A. Sander Purchases 20,000 SharesHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) CFO Dale A. Sander bought 20,000 shares of the company's stock in a transaction on Thursday, April 10th. The stock was purchased at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the transaction, the chief financial officer now directly owns 40,600 shares of the company's stock, valued at approximately $62,118. The trade was a 97.09 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.April 16, 2025 | marketbeat.comVanguard Group Inc. Purchases 543,995 Shares of Humacyte, Inc. (NASDAQ:HUMA)Vanguard Group Inc. increased its holdings in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 10.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,602,684 shares of the company's stock after acquiring aApril 16, 2025 | marketbeat.com Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address HUMA Media Mentions By Week HUMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HUMA News Sentiment▼0.650.89▲Average Medical News Sentiment HUMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HUMA Articles This Week▼1710▲HUMA Articles Average Week Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADPT News Today ETNB News Today JANX News Today MESO News Today EVO News Today SPRY News Today OCUL News Today VERA News Today ANIP News Today TVTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HUMA) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HUMA Stock Free HUMA Stock Alerts